display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - NA - all populationmML - NA - PDL1 positive
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone E1609 ...
Ipilimumab (10 mg/kg) EORTC 18071 E1609 ...
anti-PD-(L)1
nivolumab based treatment
nivolumab alone IMMUNED ... CheckMate 238
pembrolizumab based treatment
pembrolizumab alone KEYNOTE 054 ... KEYNOTE 054 ...
Immune checkpoint association
nivolumab plus ipilimumab CheckMate 915 IMMUNED ... IMMUNED ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons